Search clinical trials for: Minimal residual disease

Total 381426 results

Memorial Sloan Kettering Cancer Center
Adaptive Biotechnologies

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Zhongda Hospital

Recruiting

Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

BCR-ABL1 Fusion Protein Expression | Acute Lymphocytic Leukemia, Adult B-Cell

China
Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States
PETHEMA Foundation

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Acute Lymphoblastic Leukemia

Spain
Xianmin Song, MD

Recruiting

Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients

NGS Monitor MRD

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Hematologic and Lymphocytic Disorder | Acute Myeloid Leukemia in Remission | FLT3 Gene Mutation | Minimal Residual Disease Persistence

United States
Roswell Park Cancer Institute

Recruiting

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Colorectal Cancer | Metastatic Unresectable Sarcoma | Metastatic Malignant Neoplasm in the Lung | Resectable Sarcoma | Metastatic Soft Tissue Sarcoma | Metastatic Bone Sarcoma

United States
Novartis Pharmaceuticals
Children's Oncology Group

Recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

B-Cell Acute Lymphoblastic Leukemia

United States, Belgium, Italy, Sweden, Netherlands, Norway, United Kingdom, Germany, Canada, Spain, France, Finland, Denmark
Polish Myeloma Consortium
Janssen-Cilag Ltd.; Bioscience, S.A.

Recruiting

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)

Multiple Myeloma

Poland
Niguarda Hospital

Recruiting

Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia (AML FLT3)

Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Italy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Minimal Residual Disease | Hematopoietic Cell Transplantation Recipient | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Mantle Cell Lymphoma | CD20 Positive

United States
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland
Lund University
South Sweden Breast Cancer Group; Mrs. Berta Kamprad Foundation; U-CAN

Recruiting

Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer (SCAN-B)

Breast Neoplasms

Sweden
University of Rochester

Recruiting

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome (MRD)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Washington University School of Medicine
National Cancer Institute (NCI); Invivoscribe, Inc.; T-Cell Leukemia Lymphoma...

Completed

Minimal Residual Disease in Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
Peking University Cancer Hospital & Institute

Completed

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Colorectal Cancer | Surgery | Liver Metastases | Minimal Residual Disease | Circulating Tumor DNA

China
National Cancer Institute (NCI)

Active, not recruiting

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

Multiple Myeloma

United States, Canada
Karolinska University Hospital
Medical University of Graz; Aarhus University Hospital; Centre Hospitalier Universitaire... and other collaborators

Enrolling by invitation

GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES (GUIDEMRD)

Pancreatic Adenocarcinoma

Sweden
M.D. Anderson Cancer Center

Suspended

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Multiple Myeloma

United States
Elicio Therapeutics

Active, not recruiting

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

Colorectal Cancer | Ovarian Cancer | Cholangiocarcinoma | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Minimal Residual Disease | Gallbladder Carcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R

United States
Polish Lymphoma Research Group
AstraZeneca

Active, not recruiting

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (ACALLO)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Adverse Event | Chronic Graft-versus-host-disease | Response Rate

Poland
Fred Hutchinson Cancer Center
HighPass Bio, Inc.

Suspended

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory... and other conditions

United States
Enterome

Completed

EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (CLAUDE)

Colorectal Cancer

United States
Invitae Corporation

Active, not recruiting

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment (MARIA)

Cancer | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer

United States
Ludwig-Maximilians - University of Munich
Amgen

Withdrawn

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (DLI-TARGET)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia in Remission | B-Cell Acute Lymphoblastic Leukemia | B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation

Germany
M.D. Anderson Cancer Center
GlaxoSmithKline

Active, not recruiting

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Lymphoma | Leukemia

United States
Hospital Galdakao-Usansolo

Active, not recruiting

Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation

Multiple Myeloma
Weill Medical College of Cornell University
AstraZeneca; Celgene Corporation

Active, not recruiting

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Mantle Cell Lymphoma

United States
Crystal Mackall, MD
California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | CD19 Positive

United States
Geneplus-Beijing Co. Ltd.
Peking Union Medical College Hospital

Active, not recruiting

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Ovarian Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | Adult Acute Lymphoblastic Leukemia in Complete Remission

United States
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute | Minimal Residual Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI); Mustang Bio, Inc.

Active, not recruiting

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Refractory Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm | Minimal Residual Disease | Acute... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT)

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Prof. Christina Peters
Amgen

Terminated

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Minimal Residual Disease | ALL, Childhood

Norway, Spain, Denmark, Austria, Belgium, Czechia, France, Italy, Poland, Slovakia
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi; Amgen

Active, not recruiting

MInimal Residual Disease Adapted Strategy (MIDAS)

Multiple Myeloma

France
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States
University Hospital, Ghent

Completed

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer (OvIP1)

Ovarian Cancer | Primary Peritoneal Cancer

Belgium
Nantes University Hospital

Withdrawn

Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients. (PENTI-MIDAS)

Multiple Myeloma

France
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Mayo Clinic; University of Pennsylvania; University...

Active, not recruiting

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Aggressive | B-cell Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome and other conditions

United States

Search clinical trials for: Minimal residual disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations